DE60118362D1 - VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN - Google Patents

VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN

Info

Publication number
DE60118362D1
DE60118362D1 DE60118362T DE60118362T DE60118362D1 DE 60118362 D1 DE60118362 D1 DE 60118362D1 DE 60118362 T DE60118362 T DE 60118362T DE 60118362 T DE60118362 T DE 60118362T DE 60118362 D1 DE60118362 D1 DE 60118362D1
Authority
DE
Germany
Prior art keywords
present
hemostatic
selectin
disorders
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60118362T
Other languages
English (en)
Other versions
DE60118362T2 (de
Inventor
D Wagner
Patrick Andre
Daqing W Hartwell
Ingrid Hrachovinova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Publication of DE60118362D1 publication Critical patent/DE60118362D1/de
Application granted granted Critical
Publication of DE60118362T2 publication Critical patent/DE60118362T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE60118362T 2000-05-19 2001-05-17 VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN Expired - Fee Related DE60118362T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20573400P 2000-05-19 2000-05-19
US205734P 2000-05-19
PCT/US2001/016021 WO2001089564A2 (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity

Publications (2)

Publication Number Publication Date
DE60118362D1 true DE60118362D1 (de) 2006-05-18
DE60118362T2 DE60118362T2 (de) 2007-05-24

Family

ID=22763420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118362T Expired - Fee Related DE60118362T2 (de) 2000-05-19 2001-05-17 VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN

Country Status (8)

Country Link
US (4) US20020031508A1 (de)
EP (1) EP1289552B1 (de)
JP (1) JP2003534291A (de)
AT (1) ATE321570T1 (de)
AU (2) AU2001261735B2 (de)
CA (1) CA2408883A1 (de)
DE (1) DE60118362T2 (de)
WO (1) WO2001089564A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7060685B2 (en) * 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
WO2004004636A2 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
TW200503734A (en) * 2003-07-29 2005-02-01 Hsin-Hou Chang New use of soluble p-selectin and anthrax lethal toxin
US8377887B1 (en) 2003-07-29 2013-02-19 Hsin-Hou Chang Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin
WO2005051920A2 (en) * 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
JP2007524658A (ja) * 2003-11-19 2007-08-30 グリコミメティクス， インコーポレイテッド Ｅ−およびｐ−セレクチンの両方のための糖模倣物アンタゴニスト
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
US7807636B1 (en) * 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
DK1928892T3 (da) * 2005-08-09 2012-01-30 Glycomimetics Inc Glycomimetiske inhibitorer af PA-IL-lectin PA-IIL-lectin eller begge lectiner fra pseudomonas
PL1934236T3 (pl) 2005-09-02 2013-04-30 Glycomimetics Inc Heterobifunkcjonalne inhibitory pan-selektyny
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP3461499A1 (de) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukozyten-rekrutierungstherapie zur behandlung von wiederholung epileptischer anfälle
JP5298020B2 (ja) 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
US20100104502A1 (en) * 2006-11-06 2010-04-29 The Regents Of The University Of Michigan Compositions and methods for detecting and treating endothelial dysfunction
WO2008069999A2 (en) 2006-12-01 2008-06-12 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
AU2008216794A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
EP2288715B1 (de) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Humanserumalbumin-linker und konjugate davon
JP2011524858A (ja) * 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法
EP2318015B1 (de) * 2008-06-13 2013-08-07 GlycoMimetics, Inc. Behandlung von blutkrebs mit ausgewählten glykomimetischen verbindungen
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5726171B2 (ja) 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
SI2555789T1 (sl) * 2010-04-08 2020-10-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibirajoči peptidi, pridobljeni iz trem podobnega transkripta 1 (TLT-1), in njih uporaba
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
LT2928476T (lt) 2012-12-07 2018-05-25 Glycomimetics, Inc. Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai
US20160320416A1 (en) * 2013-12-18 2016-11-03 Siemens Healthcare Diagnostics Inc. Detection of endothelial disease
SI3227310T1 (sl) 2014-12-03 2019-11-29 Glycomimetics Inc Heterobifunkcionalni inhibitorji e-selektinov in receptorjev kemokina CXCR4
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
KR20240046288A (ko) 2016-10-07 2024-04-08 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3595645A1 (de) * 2017-03-15 2020-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmazeutische zusammensetzungen zur behandlung von thrombosen bei patienten mit einem myeloproliferativem neoplasma
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
JP7304863B2 (ja) 2017-12-29 2023-07-07 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンおよびガレクチン－３のヘテロ二機能性阻害剤
AU2019227844A1 (en) * 2018-03-02 2020-09-24 Gilles, Peter A method of modulating cell proliferation
US11707474B2 (en) 2018-03-05 2023-07-25 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5605821A (en) * 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
AU678757B2 (en) 1991-09-30 1997-06-12 Biogen, Inc. Inhibition of vascular narrowing using anti-padgem antibodies
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
CA2151142C (en) * 1992-11-16 2001-10-02 Richard D. Cummings Glycoprotein ligand for p-selectin and methods of use thereof
US5483707A (en) * 1993-03-01 1996-01-16 Meyer; Douglas S. Self standing support structure and method
WO1995025540A1 (en) * 1994-03-23 1995-09-28 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US20020040008A1 (en) * 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5763201A (en) * 1996-02-05 1998-06-09 Emory University Flow cytometry assay for heparin-induced thrombocytopenia
EP0902681B1 (de) * 1996-03-01 2002-05-22 The Regents of the University of California Hemmung der selectinbindung
US6230713B1 (en) * 1998-01-29 2001-05-15 Margaret R. Dalesandro Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6391568B1 (en) * 1998-07-15 2002-05-21 Lionheart Technologies, Inc. Method for determining platelet reactivity in a whole blood sample
MXPA01002898A (es) * 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
US6277675B1 (en) * 1999-10-28 2001-08-21 United Microelectronics Corp. Method of fabricating high voltage MOS device

Also Published As

Publication number Publication date
AU2001261735B2 (en) 2006-09-21
US20040265311A1 (en) 2004-12-30
US20080193949A1 (en) 2008-08-14
US20050202007A1 (en) 2005-09-15
JP2003534291A (ja) 2003-11-18
EP1289552A2 (de) 2003-03-12
WO2001089564A3 (en) 2002-05-10
ATE321570T1 (de) 2006-04-15
US20020031508A1 (en) 2002-03-14
US7387777B2 (en) 2008-06-17
AU6173501A (en) 2001-12-03
EP1289552B1 (de) 2006-03-29
WO2001089564A2 (en) 2001-11-29
DE60118362T2 (de) 2007-05-24
CA2408883A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE60118362D1 (de) VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
Mei et al. Arresting dentine caries with silver diamine fluoride: what’s behind it?
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE536855T1 (de) Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen
DE60108230D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
US6652840B1 (en) Bleeding control and healing aid compositions and methods of use
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
ATE431734T1 (de) Pentamidine zur behandlung von krebs
ATE506615T1 (de) Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE602004011400D1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE69920844D1 (de) Fäulnisverhinderndes mittel, verfahren zur fäulnisverhindernden behandlung und durch diese behandlung erhaltener gegenstand
Bayoumi et al. The effects of using hyaluronic acid on the extraction sockets
DE69302276T2 (de) Diagnostische Methode
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE240352T1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
ATE363075T1 (de) Verfahren zur diagnose und behandlung von metastasen und dafür nützliche zusammensetzung
AU2001261674A1 (en) Treatment methods using 17906 and uses therefor

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee